LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Provided By GlobeNewswire
Last update: Mar 28, 2025
UTRECHT, The Netherlands and PHILADELPHIA, March 28, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced recent corporate highlights and financial results for the fourth quarter and year ended December 31, 2024.
Read more at globenewswire.com
